mostly incorrect info and made it sound like it's real and expertise in clinical trials..in fact he has gotten all wrong. He is being paid for sure.
I must add that when a company is actively looking for buyers attract lower or no offers than a company doesn't need to be acquired. Think. Many had played this strategy before.
When you have solid data and with all the right patents and things...no need to panicked by day short traders or scalpers. Good weekend all.
You are intelligent indeed. Many childish posters here on this board. I am not sure about hostile but definitely will attract more offers/ bidders to pay a premium. You are right even a non biotech company has happened many times before...an acquisition offer letter..ie MU.
Hey kiddo...stop polluting the board..go find a job predicting with your crystal ball.
almost 3 times as good as placebo with the least side effect drug on the market for chronic constipation and now is testing to treat IBS Irritable Bowel Syndrome....that means more news and data will run this to 15 to 20 before buyout or partnership.
STOPS on this stock! Nothing will run it down except all of your stops...trailing stops whatsoever...no news at this time will bring it down except your stops. This has no where to go but UP at this point with all the positives at present and more news and data in upcoming conferences.
Sure is .. I said before this islike HGSI before the buyout...
I haven't sold at all at premarket waiting for the bigger piece
'Companies without an ODN on their lead compound had a median of eight years from founding to buyout—the same time to acquisition for companies with an orphan focus. However, the majority of non-orphan biotech companies gets acquired at phase 2, whereas orphan drug companies tend to get acquired at a later stage (Fig. 2b); more than 62% of the companies with an ODN on their lead were acquired at phase 3 or later compared with less than 33% of non-orphan–based companies. Therefore, although our data show that orphan drug development is indeed faster, it does not mean a shorter time to acquisition. This might be caused by acquirers needing more validation before betting on a compound with a perceived limited market potential and possible difficulties related to patient recruitment. In addition, buyers may need more clinical data to embrace a new method or platform, especially as phase 2 trials for rare diseases often involve a limited number of patients. Alternatively, the later-stage acquisitions may reflect the fact that phase 3 development of many orphan drugs, in contrast to most non-orphan drugs, often have smaller trials and can be privately financed...'
This will be acquired prior to FDA approval. Announcement should be anytime now...why?
Stock was so manipulated driving impatient holders out,,,,I really think something is boiling..
A matter of perception of the minority...adding more as it drops consensus $165 target remains
Sentiment: Strong Buy
more squeezes coming for the retail ones selling at premarket.. short at $121
bigger money pouring in
Sentiment: Strong Buy